These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 11884480)

  • 41. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients.
    Blazar BR; Taylor PA; Vallera DA
    Transplantation; 1997 Aug; 64(4):571-6. PubMed ID: 9293867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction.
    Wang F; Schwarz BT; Graham WV; Wang Y; Su L; Clayburgh DR; Abraham C; Turner JR
    Gastroenterology; 2006 Oct; 131(4):1153-63. PubMed ID: 17030185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential.
    Radulovic K; Manta C; Rossini V; Holzmann K; Kestler HA; Wegenka UM; Nakayama T; Niess JH
    J Immunol; 2012 Feb; 188(4):2001-13. PubMed ID: 22250092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin 15 and CD4⁺ T cells cooperate to promote small intestinal enteropathy in response to dietary antigen.
    Korneychuk N; Ramiro-Puig E; Ettersperger J; Schulthess J; Montcuquet N; Kiyono H; Meresse B; Cerf-Bensussan N
    Gastroenterology; 2014 Apr; 146(4):1017-27. PubMed ID: 24361466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease.
    Chen F; Maldonado MA; Madaio M; Eisenberg RA
    J Immunol; 1998 Dec; 161(11):5880-5. PubMed ID: 9834067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
    Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
    Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
    Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.
    Serody JS; Burkett SE; Panoskaltsis-Mortari A; Ng-Cashin J; McMahon E; Matsushima GK; Lira SA; Cook DN; Blazar BR
    Blood; 2000 Nov; 96(9):2973-80. PubMed ID: 11049973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impaired thymic negative selection causes autoimmune graft-versus-host disease.
    Teshima T; Reddy P; Liu C; Williams D; Cooke KR; Ferrara JL
    Blood; 2003 Jul; 102(2):429-35. PubMed ID: 12663438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of intestinal graft-versus-host reactions across mutant major histocompatibility antigens by T lymphocyte subsets in mice.
    Mowat AM; Sprent J
    Transplantation; 1989 May; 47(5):857-63. PubMed ID: 2655224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
    Koch U; Korngold R
    Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
    Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
    J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Donor MHC class II antigen is essential for induction of transplantation tolerance by bone marrow cells.
    Umemura A; Monaco AP; Maki T
    J Immunol; 2000 May; 164(9):4452-7. PubMed ID: 10779744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone marrow-derived immature dendritic cells prime in vivo alloreactive T cells for interleukin-4-dependent rejection of major histocompatibility complex class II antigen-disparate cardiac allograft.
    Buonocore S; Flamand V; Goldman M; Braun MY
    Transplantation; 2003 Feb; 75(3):407-13. PubMed ID: 12589166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
    Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
    Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.